Orient Europharma Co Ltd - ESG Rating & Company Profile powered by AI
Full ESG assessment of Orient Europharma Co Ltd can be accessed by signing in. The ESG rating for Orient Europharma Co Ltd represents the company's reporting of the United Nations SDGs. If you are employed by Orient Europharma Co Ltd and you wish to use your Sustainability rating, please get in touch.
Orient Europharma Co Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.5; made up of an environmental score of 0.0, social score of 1.6 and governance score of 0.0.
0.5
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1898 | Zota Health Care Ltd | 0.7 | Low |
1898 | cbdMD Inc | 0.7 | Low |
1924 | Orient Europharma Co Ltd | 0.5 | Low |
1924 | Beximco Pharmaceuticals Ltd | 0.5 | Low |
1924 | Acucela Inc | 0.5 | Low |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Orient Europharma Co Ltd have an accelerator or VC vehicle to help deliver innovation?
Does Orient Europharma Co Ltd disclose current and historical energy intensity?
Does Orient Europharma Co Ltd report the average age of the workforce?
Does Orient Europharma Co Ltd reference operational or capital allocation in relation to climate change?
Does Orient Europharma Co Ltd disclose its ethnicity pay gap?
Does Orient Europharma Co Ltd disclose cybersecurity risks?
Does Orient Europharma Co Ltd offer flexible work?
Does Orient Europharma Co Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Orient Europharma Co Ltd disclose the number of employees in R&D functions?
Does Orient Europharma Co Ltd conduct supply chain audits?
Does Orient Europharma Co Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Orient Europharma Co Ltd conduct 360 degree staff reviews?
Does Orient Europharma Co Ltd disclose the individual responsible for D&I?
Does Orient Europharma Co Ltd disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Orient Europharma Co Ltd disclose current and / or historical scope 2 emissions?
Does Orient Europharma Co Ltd disclose water use targets?
Does Orient Europharma Co Ltd have careers partnerships with academic institutions?
Did Orient Europharma Co Ltd have a product recall in the last two years?
Does Orient Europharma Co Ltd disclose incidents of discrimination?
Does Orient Europharma Co Ltd allow for Work Councils/Collective Agreements to be formed?
Has Orient Europharma Co Ltd issued a profit warning in the past 24 months?
Does Orient Europharma Co Ltd disclose parental leave metrics?
Does Orient Europharma Co Ltd disclose climate scenario or pathway analysis?
Does Orient Europharma Co Ltd disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Orient Europharma Co Ltd disclose the pay ratio of women to men?
Does Orient Europharma Co Ltd support suppliers with sustainability related research and development?
Does Orient Europharma Co Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Orient Europharma Co Ltd reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Orient Europharma Co Ltd involved in embryonic stem cell research?
Does Orient Europharma Co Ltd disclose GHG and Air Emissions intensity?
Does Orient Europharma Co Ltd disclose its waste policy?
Does Orient Europharma Co Ltd report according to TCFD requirements?
Does Orient Europharma Co Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Orient Europharma Co Ltd disclose energy use targets?
Does Orient Europharma Co Ltd disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Orient Europharma Co Ltd have a policy relating to cyber security?
Have a different question?
Potential Risks for Orient Europharma Co Ltd
These potential risks are based on the size, segment and geographies of the company.
Orient EuroPharma Co., Ltd., a pharmaceutical company, develops and manufactures drugs worldwide. Its prescription medicines include cardiovascular, metabolism, neurology, obstetrics and gynecology, respiratory, immunology, and anti-cancer drugs. The company also provides nutrition and baby care products, such as milk and nutritional supplements under the Karihome, Babecare, and Ostricare brands; and healthcare supplements, such as thermal water for the treatment of oral and periodontal diseases under the Buccotherm name. In addition, the company offers essences, creams, lotions, eye creams, facial treatment toners, and skin repairing essences under the AGLab name; skincare oils, body lotions, and dry skin gels under the Bio-Oil name; and children skincare products under the Mister Baby brand, as well as operates ISISPHARMA, a dermatology laboratory specialized in the development and distribution of dermo-cosmetic products. Further, it engages in the research and development of Multikine, an immunotherapy drug for head and neck cancer, which is in Phase III clinical study; NC-6004, a platinum-based micelle chemotherapeutic drug that is in Phase III clinical study; ASC-J9, a molecular chemical entity drug that has completed Phase IIb clinical study for androgen receptor degradation; and 2ccPA, a derivative of phospholipid to patients with symptomatic osteoarthritis of the knee, which is in Phase I clinical trail. The company was founded in 1982 and is based in Taipei, Taiwan.